Glen Carter, senior author of the study from the University of Melbourne and the Doherty Institute, said the study challenges the previously-held belief that rifaximin is low-risk for causing AMR.
“We’ve shown that rifaximin makes VRE resistant to daptomycin in a way that has not been seen before,” he said in a media release.
“It is also of concern that these daptomycin-resistant VRE might be transmitted to other patients in the hospital; a hypothesis that we are presently investigating.”
The authors of the new study said the findings highlight the critical need for effective genomics-based surveillance to detect emerging AMR.
SANGHA KOMMUNE (SSR) 